Holen Sie sich die Stockscreener-App
21.99
4.31%
-0.99
Handel nachbörslich:
21.91
-0.08
-0.36%
Schlusskurs vom Vortag:
$22.98
Offen:
$23
24-Stunden-Volumen:
237.90K
Relative Volume:
0.41
Marktkapitalisierung:
$693.21M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-17.02%
1M Leistung:
-30.35%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$20.93
$23.47
1-Wochen-Bereich:
$20.93
$26.82
52-Wochen-Spanne:
$13.88
$33.20
Evommune Inc Stock (EVMN) Company Profile
Firmenname
Evommune Inc
Sektor
Branche
Telefon
(650) 223-7745
Adresse
1841 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
21.99 | 724.42M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-22 | Eingeleitet | Oppenheimer | Outperform |
| 2026-01-08 | Eingeleitet | Raymond James | Strong Buy |
| 2026-01-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-12-01 | Eingeleitet | Evercore ISI | Outperform |
| 2025-12-01 | Eingeleitet | Leerink Partners | Outperform |
| 2025-12-01 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-12-01 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Evommune Inc Aktie (EVMN) Neueste Nachrichten
Leerink reiterates Evommune stock rating after conference chat - Investing.com
RBC Capital initiates Evommune stock with outperform rating By Investing.com - Investing.com Canada
Evommune, Inc. (NYSE:EVMN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade - The Globe and Mail
Evommune initiated with an Outperform at RBC Capital - TipRanks
Evommune (NYSE:EVMN) Trading Down 6.7%Here's What Happened - MarketBeat
Evommune, Inc. (EVMN) Receives a Rating Update from a Top Analyst - The Globe and Mail
Evommune (NYSE:EVMN) Trading 6.9% HigherTime to Buy? - MarketBeat
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlight - PharmiWeb.com
Evommune Reports Q4 2025 Results and Pipeline Progress - TipRanks
Evommune reports Q4 EPS ($1.43), consensus (84c) - TipRanks
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights - The Joplin Globe
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
Evommune (EVMN) Insider Trading Activity 2026 - MarketBeat
Evommune, Inc.: Lead in MRGPRX2 Modulation and Differentiated EVO756 Profile Support Buy Rating - TipRanks
EVMN Technical Analysis & Stock Price Forecast - Intellectia AI
Evommune (NYSE:EVMN) Trading Down 10.2%Time to Sell? - MarketBeat
Evommune (EVMN) Price Target Increased by 37.87% to 55.08 - Nasdaq
Evommune CEO Luis Peña Reveals What’s Behind Company’s Post-IPO Success - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Charles River Labs (CRL) - The Globe and Mail
Evommune (NYSE:EVMN) Trading Down 7.4%Time to Sell? - MarketBeat
Morgan Stanley Maintains Overweight on Evommune (EVMN) Feb 18 2026 - Meyka
Eczema Pipeline 2026 Outlook: 100+ Clinical Assets and 3 Key Late-Stage Candidates to Watch, analyses DelveInsight - openPR.com
Technical Analysis - Intellectia AI
Evommune Announces $125 Million Private Placement - The AI Journal
Evommune announces $125 million private placement - The Pharma Letter
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Finviz
Benzinga Stock Whisper Index Analysis - Intellectia AI
Evommune, Inc. Common Stock (NYSE:EVMN) Stock Quote - FinancialContent
Evommune raises $125 million in private placement to fund R&D By Investing.com - Investing.com Canada
Assessing Evommune (EVMN) Valuation After Strong Phase 2a Eczema Data And US$125.3m Placement - Yahoo Finance
Evommune, Inc. (NYSE:EVMN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Evommune (NYSE:EVMN) Shares Gap UpHere's Why - MarketBeat
Weekly Buzz:FDA Okays NVCR's Cancer Device; RGNX Gets CRL;ONCO To Buy XBOT; PHIO's PH-762 Sets Pace - RTTNews
Evommune Inc on Feb 12, enters securities purchase agreement with investors - marketscreener.com
Evommune Announces $125 Million Private Placement Financing - TipRanks
Evommune Inc On Feb 12, Enters Securities Purchase Agreement With Investors - TradingView
Evommune Signs Multiple Material Agreements - TradingView
Evommune raises $125M privately - MSN
Evommune raises $125 million in private placement to fund R&D - Investing.com Australia
Evommune to Raise $125 Million Via Private Placement - marketscreener.com
Evommune's stock surges on strong results for new eczema drug - MSN
Evommune Secures $125M in Private Placement Agreement - Intellectia AI
Evommune’s atopic dermatitis drug meets primary endpoint in phase 2a trial - Investing.com Nigeria
Evommune Enters Private Placement Agreement for $125 Million - Intellectia AI
Evommune Inc (EVMN-N) Insider Trade Summaries - The Globe and Mail
Evommune Stock Cools Off After Big Rally On Successful Eczema Trial - Bitget
Finanzdaten der Evommune Inc-Aktie (EVMN)
Es liegen keine Finanzdaten für Evommune Inc (EVMN) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):